Boston Scientific (BSX) is on track to be the highest performing large cap medtech company, RBC Capital Markets said in a note emailed Friday.
The firm said it had come away more bullish on the company's 2025 setup after catching up with the company and its investors.
The firm cited the company's diversified portfolio and category leadership, as well as pipeline initiatives, as reasons to be positioned attractively in 2025.
RBC Capital also said the company's 2025 guidance was "prudent and achievable," but one that it is positioned to beat and raise from.
The firm has an outperform rating on the stock with a price target of $105.
Price: 98.76, Change: +0.59, Percent Change: +0.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。